ProCE Banner Activity

My Take on Tucatinib and Trastuzumab for HER2-Positive Metastatic Colorectal Cancer

Conference Coverage
Clinical Thought

Dr John Strickler provides his insights on the MOUNTAINEER trial with tucatinib and trastuzumab and other key takeaways on how to manage HER2 positive metastatic colorectal cancer.

Released: August 10, 2022

Expiration: August 09, 2023

No longer available for credit.

Share

Faculty

John Strickler

John Strickler, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Seagen Inc.

Faculty Disclosure

Primary Author

John Strickler, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Duke University
Durham, North Carolina

John Strickler, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, GlaxoSmithKline, Inivata, Mereo BioPharma, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Takeda, Viatris; researcher (funds paid to institution): AbbVie, Amgen, AStar D3, Bayer, Curegenix, Daiichi Sankyo, Erasca, Gossamer Bio, Nektar, Roche/Genentech, Sanofi, Silverback Therapeutics.